May 22, 2026

RA Outcomes Improved in KURAMA Cohort

Ten-year observational data showed lower disease activity and functional disability coinciding with broader use of biologic and targeted synthetic therapies.

Conexiant

May 22, 2026

JAK Monotherapy Shows Efficacy in RA Review

A systematic review found Janus kinase inhibitor monotherapy improved outcomes vs methotrexate or placebo, but direct comparisons with combination therapy were limited.

Conexiant

May 21, 2026

Rehab May Improve Function in AS

Supervised rehabilitation and exercise-based therapies may improve function, pain, and bone health in ankylosing spondylitis, according to a new review.

Conexiant

May 20, 2026

Combination Therapy Shows Potential in Psoriasis, Obesity

Researchers assess whether adding tirzepatide to ixekizumab affects skin and weight outcomes in adults with moderate to severe plaque psoriasis.

Conexiant

May 19, 2026

Top 10 High-Impact Clinical Guidance Updates for Board-Certified Physicians

A structured framework of guidelines, consensus statements, therapies, and clinical tools used across practice.

Conexiant

May 18, 2026

FDA Clears Golimumab Biosimilars

New biosimilars enter the market with pharmacy-level substitution eligibility for rheumatology and gastroenterology indications.

Conexiant

May 18, 2026

Top 10 States with the Lowest Costs for Running a Medical Practice

These 10 states posted some of the lowest 2026 Medicare practice expense GPCI among states that CMS treats as a single statewide locality, with broader price levels and selected malpractice or tax indicators adding context.

Conexiant

May 11, 2026

Primary Care Is Starving While Training Hospitals Feast

Internal medicine residents are choosing primary care at the lowest rates in a decade — and the system is built to make sure they do.

Conexiant

May 11, 2026

Serum Urate Goals Tied to Lower CV Risk

Patients with gout who reached serum urate targets had modestly higher 5-year cardiovascular event-free survival, with associations strongest among high-risk patients

Conexiant

May 08, 2026

Tofacitinib vs Adalimumab Findings Require Caution in RA

Meta-analysis favored tofacitinib for some rheumatoid arthritis outcomes, but high heterogeneity, dose-dependent effects, and JAK inhibitor safety concerns complicate interpretation.

Conexiant